Welcome to our dedicated page for Altamira Therapeutics Ltd. Common Shares 0.01 SF (Bermuda) news (Ticker: CYTO), a resource for investors and traders seeking the latest updates and insights on Altamira Therapeutics Ltd. Common Shares 0.01 SF (Bermuda) stock.
Altamira Therapeutics Ltd., formerly known as Auris Medical, is a pioneering company dedicated to developing therapeutics that address significant unmet medical needs. Founded in 2003 and headquartered in Hamilton, Bermuda, with principal operations in Basel, Switzerland, Altamira Therapeutics trades on the NASDAQ Capital Market under the symbol “CYTO”.
Altamira is actively engaged in three primary areas:
- RNA Therapeutics: Utilizing innovative platforms such as OligoPhore™ and SemaPhore™, the company focuses on developing RNA-based therapies targeting extrahepatic sites. These platforms, currently in the preclinical stage, leverage proprietary peptides to form nanoparticles capable of delivering therapeutic RNA to tissues affected by conditions like solid tumors and inflammation.
- Nasal Sprays: The commercially available Bentrio™ nasal spray offers protection against airborne viruses and allergens, while AM-125, which is in Phase 2 clinical trials, targets the treatment of vertigo.
- Inner Ear Disorders: Altamira is progressing with Phase 3 development of Keyzilen® and Sonsuvi® for the intratympanic treatment of tinnitus and hearing loss, respectively.
Altamira Therapeutics is committed to advancing its pipeline through rigorous research and strategic collaborations. Recently, the company has made significant strides with its RNA therapies, as highlighted in studies such as Huang et al. (2021) and Strand et al. (2019), demonstrating the potential of targeting KRAS mutations in cancer. Moreover, ongoing research in peptide-based nanoparticles and NF-κB subunit targeting shows promising applications in inflammatory diseases and cancer treatment.
In the field of nasal sprays, Altamira's Bentrio™ has shown efficacy in clinical trials, with recent studies like Becker et al. (2024) validating its use in protecting against seasonal allergic rhinitis.
Financially, Altamira Therapeutics has reclassified its Bentrio business as discontinued operations, focusing its resources on advancing its core therapeutic areas. The company's investor communications emphasize its forward-looking strategy and commitment to innovation.
Stay updated with the latest news and developments from Altamira Therapeutics by visiting their official website and connecting through their social media channels.
Rhea-AI Summary
Altamira Therapeutics Ltd. (Nasdaq: CYTO) announced the publication of a peer-reviewed study showing enhanced cell transduction with adeno-associated virus (AAV) vectors using their peptide-based delivery technology. The study demonstrated increased potency, potentially reducing AAV immunogenicity and resistance to AAVs in certain cell types. The research evaluated 76 melittin derivatives, including p5RHH, which successfully enhanced cell transduction and transduced cell lines typically resistant to AAVs. In vivo studies in mice showed significant liver transduction enhancements with the addition of p5RHH to AAV capsids of several serotypes, up to four weeks after administration. Altamira's technology has the potential to lower the risk of immune responses and increase the safety of AAV-based vectors, opening new possibilities in gene therapy for cells and tissues typically resistant to transduction.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.05%
Tags
-
Rhea-AI Summary
Altamira Therapeutics Ltd. (Nasdaq: CYTO) has filed a second provisional patent application with the USPTO for its polyKRASmut siRNA, showing a 65-91% knockdown of KRAS mutations in colorectal, non-small cell lung, and pancreatic cancer cell lines. The nanoparticles developed as AM-401 aim to provide broad coverage of different KRAS mutations in human cancer treatment. The data suggests that polyKRASmut siRNA has the potential to knock down other untested mutations, making it a promising treatment for severe types of cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.57%
Tags
-
Rhea-AI Summary
Altamira Therapeutics Ltd. (CYTO) to Present at 3rd Annual mRNA-Based Therapeutics Summit. Altamira's flagship programs, AM-401 and AM-411, target KRAS-driven cancer and rheumatoid arthritis, showcasing the technology's ability to enhance therapeutic efficacy. Covadonga Pañeda, Ph.D., Altamira's COO, will present on 'Delivery of therapeutic RNA in inflammation and cancer using peptide-based nanoparticles' at the conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Altamira Therapeutics Ltd. (Nasdaq: CYTO) has announced that it has regained compliance with the minimum bid price requirement set by The Nasdaq Stock Market. This comes after the company was notified of its failure to maintain a minimum closing bid price of at least $1.00 per share for 30 consecutive trading days, leading to a reverse stock split of its common shares at a ratio of 1-for-20. Altamira has now evidenced a closing bid price of its common shares at or greater than $1.00 per share for at least 10 consecutive business days, regaining compliance with Nasdaq Listing Rule 5550(a)(2) and the minimum equity requirements for continued listing on Nasdaq.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.41%
Tags
-
Rhea-AI Summary
Altamira Therapeutics Ltd. (Nasdaq: CYTO) announced a partial spin-off of its Bentrio business, marking the first step in its transition to become a 'pure play' RNA delivery company. The transition is expected to be completed in 2024 through partnering of further legacy assets. The company's spending levels and cash burn are aligned with strategic repositioning and are expected to decrease significantly in 2024. Altamira is now free of financial debt following the early repayment of a convertible loan and expects to regain full compliance with Nasdaq continued listing rules through a reverse split.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-53.9%
Tags
-
Rhea-AI Summary
Altamira Therapeutics Ltd. (Nasdaq: CYTO) will host an Investor and Business Update Call on December 11, 2023, at 8:30 a.m. ET to discuss the development of therapeutics for unmet medical needs. The presentation will be available via teleconference or webcast, and a replay will be accessible through the webcast link.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.08%
Tags
Rhea-AI Summary
Altamira Therapeutics Ltd. (Nasdaq: CYTO) has completed a partial spin-off of Bentrio® to focus on RNA delivery activities. The company retains 49% in Altamira Medica AG and secures 25% of future licensing revenue. Altamira regained compliance with the minimum stockholders' equity requirement set by Nasdaq after boosting its equity position through a public offering of common shares, partial amortization of convertible debt, and the partial spin-off of Bentrio® activities. The spin-off involved the transfer of a 51% stake in Altamira Medica AG, with Altamira receiving a cash consideration of CHF 2,040,000. Nasdaq will continue to monitor the company's compliance with the stockholders' equity requirement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
180.43%
Tags
-
Rhea-AI Summary
Altamira Therapeutics Ltd. (CYTO) Initiates Strategic Repositioning to Focus on Core RNA Delivery Technology
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
180%
Tags
-
Rhea-AI Summary
Altamira Therapeutics Ltd. (Nasdaq:CYTO) receives 'Intention to Grant' notice from European Patent Office for its patent application titled 'Intranasal Composition Comprising Betahistine', providing key intellectual property protection for the Company's intranasal betahistine program (AM-125) in Europe.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.83%
Tags
Rhea-AI Summary
Altamira Therapeutics announces positive efficacy data from NASAR clinical trial for Bentrio nasal spray in treatment of seasonal allergic rhinitis
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.72%
Tags
FAQ
What is the current stock price of Altamira Therapeutics Ltd. Common Shares 0.01 SF (Bermuda) (CYTO)?
The current stock price of Altamira Therapeutics Ltd. Common Shares 0.01 SF (Bermuda) (CYTO) is $0.423 as of November 22, 2024.
What is the market cap of Altamira Therapeutics Ltd. Common Shares 0.01 SF (Bermuda) (CYTO)?
The market cap of Altamira Therapeutics Ltd. Common Shares 0.01 SF (Bermuda) (CYTO) is approximately 1.7M.
What areas of therapeutics does Altamira Therapeutics focus on?
Altamira Therapeutics focuses on RNA therapeutics, nasal sprays for protection against airborne viruses and allergens, and treatments for inner ear disorders.
What are the main products of Altamira Therapeutics?
Main products include the Bentrio™ nasal spray for virus and allergen protection, AM-125 for vertigo treatment, and RNA-based therapies using the OligoPhore™ and SemaPhore™ platforms.
Where is Altamira Therapeutics headquartered?
Altamira Therapeutics is headquartered in Hamilton, Bermuda, with key operations in Basel, Switzerland.
What is the stock symbol for Altamira Therapeutics?
Altamira Therapeutics trades on the NASDAQ Capital Market under the symbol “CYTO”.
What recent achievements has Altamira Therapeutics made in RNA therapeutics?
Altamira has made significant progress in RNA therapeutics, with studies demonstrating the potential of targeting KRAS mutations in cancer and using peptide-based nanoparticles for drug delivery.
What stage are the inner ear disorder treatments in?
Keyzilen® and Sonsuvi®, targeting tinnitus and hearing loss respectively, are currently in Phase 3 clinical development.
How does the OligoPhore™ platform work?
The OligoPhore™ platform complex therapeutic RNAs with proprietary peptides to form nanoparticles, enabling systemic delivery to tissues affected by leaky vasculature, such as in tumors and inflammatory conditions.
What are the recent clinical trial results for Bentrio™?
Recent studies, including those by Becker et al. (2024), have shown that Bentrio™ is effective in protecting against seasonal allergic rhinitis.
What is the significance of recent financial reclassifications for Altamira?
Altamira has reclassified its Bentrio business as discontinued operations to better focus resources on advancing its core therapeutic areas.
How can investors stay updated with Altamira Therapeutics?
Investors can stay updated by visiting Altamira's official website, following their social media channels, and subscribing to their official communications.
Altamira Therapeutics Ltd. Common Shares 0.01 SF (Bermuda)